Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.46 |
| ▸ | CTSK | P43235 | 15/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758095 | 0.82 | CTSS (0.36) | CTSSCTSKCTSLCTSB | |
| SCHEMBL8691068 | 0.78 | CTSK (0.40) | CTSSCTSKCTSLCTSB | |
| SCHEMBL18907822 | 0.76 | MMP8 (0.34) | — | |
| SCHEMBL2746199 | 0.74 | CTSS (0.38) | CTSSCTSKCTSLCTSB | |
| SCHEMBL18909748 | 0.74 | CYP2D6 (0.50) | — | |
| SCHEMBL17447513 | 0.73 | CTSS (0.40) | CTSSCTSKCTSLCTSB | |
| SCHEMBL5541518 | 0.72 | ALDH1A1 (0.47) | — | |
| SCHEMBL14108227 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL3884426 | 0.71 | ALDH1A1 (0.50) | CTSSCTSKCTSL | |
| SCHEMBL10266048 | 0.71 | TET2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3380478-B1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2017091600-A9 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091600-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | CTSS 1697/4885CTSK 1234/4885CTSL 2612/4885 |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | ACACA, ACACB, PC | CTSS 2678/4885CTSK 1399/4885CTSL 3177/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | CTSS 2353/4885CTSK 1145/4885CTSL 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.